Bayer to Advance its Investigational Cell and Gene Therapy for Parkinson's Disease
Shots:
- BlueRock completes the 1st patient dosing in the P-I study of DA01 in patients with Parkinson's disease across the US & Canada. The program is currently recruiting & evaluating patients in an ongoing P-Ib study
- The 1EP of study is to assess safety & tolerability of DA01 cell transplantation @1yr. post-transplant & 2EPs are to assess the evidence of transplanted cell survival & motor effects @1/2 yrs. post-transplant and to evaluate safety & tolerability @2yrs. along with the feasibility of transplantation
- Bayer also initiates a gene therapy trial via AskBio in an ongoing P-Ib clinical study to assess the safety & preliminary efficacy of AVV gene therapy in 10 patients with PD in the US
| Ref: Business Wire | Image: Business Standard
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com